Dr. Huajie Jin (Lily) is a Senior Lecturer and Deputy Head at King’s Health Economics (KHE), located at the Institute of Psychiatry, Psychology, and Neuroscience at King’s College London (KCL). She also holds an Honorary Associate Professorship at the Division of Psychiatry, University College London (UCL), and at the Health Technology Assessment Research Department of the Shanghai Health Development Research Centre.

Lily has intensive research experience in health economic evaluation, including model-based and/or trial-based economic evaluation, cost-of-illness study and budget-impact analysis. She is particularly interested in the development and reuse of whole disease models. She has been working on a wide range of different disease areas, including mental health disorders, cancers, kidney diseases, infectious diseases, and orthodontics.

Lily welcomes PhD applications about applied and/or methodological research related to health economic evaluation.

Career

Lily gained BSc in Medicine from Southeast University (PRC) in 2008 and completed MSc in International Health Policy (health Economics stream) from LSE in 2009. Following the completion of MSc, Lily worked on the National Institute for Health and Care Excellence (NICE) clinical guidelines for three years. During this period, Lily was the principal health economist of three NICE clinical guidelines and three NICE Medtech innovation briefings (MIBs).

In 2013 Lily joined KCL as Senior Health Economist, whilst working she completed her part time PhD in 2019, which aims to build an individual patient level whole disease model covering the entire care pathway for schizophrenia service in the UK. Her PhD study was awarded “PhD of the year” in Health Service and Population Research Department. Lily was appointed as Senior Lecturer in Health Economics in 2021.

Selected current projects

Lily is currently leading the health economic analysis for the following projects:

· PROSPECTS (https://medphys.royalsurrey.nhs.uk/prospects/). A multi-centre clinical trial which aims to compare the cost-effectiveness of breast cancer screening using DBT + 2DDM or S2D with screening using 2DDM, based on data for 100,000 women aged 50-70 years who are attending routine breast screening.

· PROTID (https://www.protid-africa.com/project/). A multinational clinical trial which will randomise 3,000 people with diabetes and latent tuberculosis infection in Tanzania and Uganda to a 12-week course of rifapentine and isoniazid preventive therapy or placebo.

· STARRT-AKI (https://www.thebottomline.org.uk/summaries/icm/starrt-aki/). A multinational clinical trial which aims to compare the cost-effectiveness of accelerated initiation of renal replacement therapy compared to standard initiation in 2,927 critically ill patients with severe acute kidney injury.

· YouScreen (https://www.eastlondonhcp.nhs.uk/aboutus/youscreen.htm). A 3-year pragmatic implementation feasibility clinical trial which aims to compare the cost-effectiveness of vaginal self-sampling with the standard call/recall system based on data for 31,000 women and people with a cervix in north and east London.

 Lily is also involved in early economic modelling for new health technologies under development.

Honorary appointments

• 2023 - Present: Honorary Associate Professor, Division of Psychiatry, UCL
• 2021 - Present: Honorary Associate Professor, Health Technology Assessment Research Department, Shanghai Health Development Research Centre, Shanghai, P.R. China
• 2011-2013: Honorary Research Fellow of the Medical Department, Cardiff University
• 2012-2013: Honorary Research Associate at the Swansea Centre for Health Economics, Swansea university

Public engagement

• 2021 - Present: Health economic advisor to the scrutiny panel for planned care in Wales.
• 2013 - Present: Peer view papers for a range of journals, including The Lancet Infectious Disease, The Lancet Global Health, The Lancet Public Health, Bulletin of the World Health Organization, Value in Health and PharmacoEconomics etc.

Selection of recent public presentations

• Sep 2023. Oral presentation of “Cost-effectiveness of Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury – An economic evaluation based on trial data, registry data and economic model”, HECUN workshop, Paris, France.
• Sep 2023. Oral presentation of “The role of HTA in incentivising innovation in pharmaceutical companies” (virtual), ISPOR China 2023, Xi’an, China.
• Sep 2023. Oral presentation of “Applications of Whole Disease Modelling” (virtual), webinar, Trinity College Dublin, Dublin, Ireland.
• June 2023. Oral presentation of “Preliminary results of a national expert survey about key issues in the methods and process of Health Technology Assessment in China” (virtual), Peking University, Beijing, ChinaDec 2021. Oral presentation “Use of Whole Disease Models (WDM) and Pathway Models in Health Economic Research — Benefits and Risks” at Virtual ISPOR Europe 2021, Milan, Italy.
• June 2021. Paper accepted for oral discussion at HESG – “Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies”, online conference, Cambridge, UK.
• June 2021. Oral presentation of “The use and value of Whole Disease Modelling Approach in HTA” at Shanghai HTA centre, online seminar, Shanghai, China.
• Nov 2020. Oral presentation of spotlight session “Novel Methods for Modelling Treatment Sequencing” at Virtual ISPOR Europe 2020, Milan, Italy.
• Aug 2020. Oral presentation of “Introducing the Whole Disease Modelling (WDM) Approach Online Seminar” at the Health Intervention and Technology Assessment Program (Hitap) online seminar, Nonthaburi, Thailand.
• Jan 2020. Oral presentation of the findings of the schizophrenia whole disease model at the Health Economics and Decision Science (HEDS) seminar, the University of Sheffield, Sheffield, UK.
• Sep 2019. Oral presentation of the findings of the schizophrenia whole disease model at the Health Economics Research Centre (HERC) Seminar Series, University of Oxford, UK.